Generic Name and Formulations:
Ceftazidime 1g, 2g; pwd for IM or IV inj, or IV infusion after reconstitution; sodium content 2.3mEq/g.
Indications for TAZICEF:
Susceptible infections including lower respiratory tract (eg, pneumonia), skin and skin structure, UTIs, septicemia, bone and joint, gynecologic (eg, endometritis, pelvic cellulitis), meningitis, intraabdominal (eg, peritonitis).
Administer in upper outer quadrant of the gluteus maximus or lateral part of the thigh. Usual dose: 1g IV or IM every 8–12 hours. Uncomplicated UTIs: 250mg IV or IM every 12 hours. Complicated UTIs: 500mg IV or IM every 8–12 hours. Bone and joint: 2g IV every 12 hours. Uncomplicated pneumonia, mild skin and skin structure: 500mg–1g IV or IM every 8 hours. Serious gynecologic, intraabdominal, meningitis, or very severe life threatening (eg, immunocompromised): 2g IV every 8 hours. Lung infections: 30–50mg/kg IV every 8 hours; max of 6g/day. Renal dysfunction: CrCl 31–50mL/min: 1g every 12 hours; CrCl 16–30mL/min: 1g every 24 hours; CrCl 6–15mL/min: 500mg every 24 hours; CrCl <5mL/min: 500mg every 48 hours. Hemodialysis: 1g loading dose then 1g after each dialysis session. Peritoneal dialysis: 1g loading dose then 500mg every 24 hours.
Neonates: 30mg/kg IV every 12 hours. 1 month-12 years: 30–50mg/kg IV every 8 hours, max of 6g/day. Renal impairment: reduce dose.
Penicillin or other allergy. Renal or hepatic impairment, poor nutritional state, long term use: monitor prothrombin time. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Nephrotoxicity with concomitant aminoglycosides, diuretics (eg, furosemide). Antagonized by chloramphenicol. False (+) glucose test with Clinitest, Benedict's, or Fehling's soln.
Hypersensitivity reactions (eg, rash, pruritus, fever), local reactions, GI upset, elevated liver enzymes.
Vials 1g—1, 10, 25
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib